Peter Honig work email
- Valid
- Valid
- Valid
Peter Honig personal email
- Valid
Peter Honig phone numbers
Dr. Peter Honig is an experienced leader in the strategic and tactical aspects of drug and vaccine development with expertise in clinical pharmacology, clinical program and clinical trial design, compliance, medical product safety, and medical product regulation. Before joining Pfizer, he held leadership positions at AstraZeneca and Merck. Prior to joining Merck, Dr. Honig founded and was the first Director of the Office of Drug Safety in the Food and Drug Administration's (FDA) Center for Drug Evaluation and Research He is a past President of American Society of Clinical Pharmacology and Therapeutics (ASCPT)and is the PhRMA representative to the International Conference on Harmonization (ICH) Steering Committee. He is also currently a Board Director at Celladon and Orexigen Therapeutics and an industry representative to the Executive Committee of the Biomarkers Consortium. He received his baccalaureate, medical and public health degrees from Columbia University in New York is board-certified in internal medicine and clinical pharmacology and has authored numerous peer reviewed publications and book chapters and is a current Associate Editor of Clinical Pharmacology and Therapeutics.
Blackstone
View- Website:
- blackstone.com
- Employees:
- 7458
- Company phone:
- +1 (212) 583-5000
- Company email:
- pressinquiries@blackstone.com
-
Managing DirectorBlackstoneCollegeville, Pa, Us
-
Managing DirectorBlackstone Jul 2023 - PresentNew York, Ny, Us -
Executive Advisor To Blackstone Life SciencesBlackstone Feb 2022 - Jul 2023New York, Ny, Us
-
Member Board Of DirectorsDrug Information Association (Dia) May 2021 - Present -
Board MemberCentre Of Regulatory Excellence (Core) Aug 2020 - PresentThe Centre of Regulatory Excellence (CoRE) was established with support from Singapore’s Economic Development Board, Health Sciences Authority and Ministry of Health as the first Asian Centre dedicated to addressing the capacity development and policy innovation needs of national health product and health systems regulators, the biomedical industry, pharmaceutical and medical device companies, and biomedical researchers
-
Advisory Board MemberThe Accelerating Therapeutics For Opportunities In Medicine (Atom) Consortium Jan 2020 - PresentThe Accelerating Therapeutics for Opportunities in Medicine (ATOM) consortium is a public-private partnership with the mission of transforming drug discovery by accelerating the development of more effective therapies for patients
-
Independent Board MemberAeriumtx Mar 2022 - May 2024Aerium is dedicated to the discovery & development of antibodies and small molecule antivirals against SARS-CoV-2 and other epidemic & pandemic threats. https://www.aeriumtx.com
-
Member Board Of DirectorsAlopexx Enterprises, Llc Oct 2021 - Sep 2023Concord, Massachusetts, UsAlopexx is clinical stage biotechnology company focusing on developing novel, broad-spectrum immune-mediated therapeutics for the prevention and treatment of a wide range of bacterial, fungal and parasitic microbial infections. -
Board MemberSesen Bio Jul 2021 - Mar 2023Sesen Bio, Inc. is a late-stage clinical company advancing targeted fusion protein therapeutics for the treatment of patients with cancer. https://www.sesenbio.com
-
Scientific Advisory BoardTravecta Therapeutics Oct 2021 - Sep 2022Travecta is an emerging biotech company utilizing its novel Blood-Brain Barrier Transport Platform to develop a proprietary pipeline of molecules that treat disorders of the central nervous system. The Travecta Platform leverages our proprietary knowledge of the MFSD2a Transport for the targeted delivery of therapeutic agents to the brain.
-
Associate EditorClinical Pharmacology And Therapeutics Jan 2009 - Nov 2021
-
SvpPfizer May 2014 - Jul 2021New York, New York, Us -
Management Committee MemberInternational Committee On Harmonization Feb 2002 - Jul 2021The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) is unique in bringing together the regulatory authorities and pharmaceutical industry to discuss scientific and technical aspects of pharmaceuticals and develop ICH guidelines. Since its inception in 1990, ICH has gradually evolved, to respond to increasingly global developments in the pharmaceutical sector and these ICH guidelines are applied by a growing number of regulatory authorities. ICH's mission is to achieve greater harmonisation worldwide to ensure that safe, effective and high quality medicines are developed, and registered and maintained in the most resource efficient manner whilst meeting high standards.
-
Executive CommitteeBiomarkers Consortium Mar 2013 - May 2021The Biomarkers Consortium is a public-private biomedical research partnership managed by the Foundation for the National Institutes of Health (FNIH) that endeavors to discover, develop and seek regulatory approval for biological markers (biomarkers) to support new drug development, preventative medicine and medical diagnostics.
-
Advisory Board MemberExcellentia Global Partners Jan 2010 - Jan 2020
-
Board Of DirectorsOrexigen Therapeutics Mar 2010 - Jun 2018La Jolla, Ca, Us -
Board DirectorCelladon Corporation Jan 2014 - Mar 2016
-
Head, Global Regulatory AffairsAstrazeneca Jul 2010 - May 2014Cambridge, Cambridgeshire, Gb -
Vp And Head, Global Regulatory AffairsAstrazeneca Jul 2010 - May 2014Cambridge, Cambridgeshire, Gb
-
Member, Committee On Scientific Standards For Studies On Modified Risk Tobacco ProductsInstitue Of Medicine Jun 2010 - Sep 2011
-
Clinical Advisory BoardGeneration Health Jan 2010 - Sep 2010
-
Senior AdvisorB&D Consulting Jan 2010 - Jun 2010Washington, Dc, Us -
Pharmaceutical ConsultantPeter Honig Regulatory And Medical Advisors, Llc Jan 2010 - May 2010
-
Merck Research LaboratoriesMerck Mar 2002 - Dec 2009Rahway, New Jersey, UsWorldwide Regulatory Affairs and Product Safety -
Medical OfficerFda Center For Drug Evaluation And Research 1990 - 2002Silver Spring, Md, Us -
Assistant ProfessorGeorgetown University Jul 1989 - Oct 1990Washington, Dc, Us -
HousestaffNorthwestern University 1982 - 1985
Peter Honig Skills
Peter Honig Education Details
-
Uniformed Services UniversityClinical Pharmacology -
Columbia UniversityMph
-
Columbia University Vagelos College Of Physicians And SurgeonsDoctor Of Medicine (Md)
-
Columbia UniversityHistory
Frequently Asked Questions about Peter Honig
What company does Peter Honig work for?
Peter Honig works for Blackstone
What is Peter Honig's role at the current company?
Peter Honig's current role is Managing Director.
What is Peter Honig's email address?
Peter Honig's email address is pe****@****zer.com
What is Peter Honig's direct phone number?
Peter Honig's direct phone number is (212) 733*****
What schools did Peter Honig attend?
Peter Honig attended Uniformed Services University, Columbia University, Columbia University Vagelos College Of Physicians And Surgeons, Columbia University.
What skills is Peter Honig known for?
Peter Honig has skills like Clinical Development, Regulatory Affairs, Clinical Trials, Pharmaceutical Industry, Fda, Pharmacovigilance, Drug Development, Clinical Research, Vaccines, Biotechnology, Regulatory Submissions, Oncology.
Who are Peter Honig's colleagues?
Peter Honig's colleagues are Jacob Kleinberger, Hank (Hyun Woo) Yu, Tiffany Aller, Mshrm, Jee Hee Son, Colin Fitzpatrick, Kelly Hyunsoo Jin, Prodip Mondal.
Free Chrome Extension
Find emails, phones & company data instantly
Aero Online
Your AI prospecting assistant
Select data to include:
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial